Novel approaches to the nutritional management of the allergic infant.
The increased prevalence of atopic diseases, i.e. atopic eczema, allergic rhinitis and asthma, has been described as the epidemic of the 21st century in Western societies. New approaches in the fight against allergic diseases are clearly called for, the target being the persistence of the allergic responder pattern beyond infancy. The advantage afforded by elimination diets lies in the silencing of specific allergic inflammation induced by an offending food. Novel nutritional approaches, beyond the treatment of food allergies, have recently attracted research interest subsequent to the identification of the immunomodulatory potential of specific dietary compounds. Dietary lipids as immunomodulators may prevent allergic sensitization by down-regulating inflammatory response whilst protecting the epithelial barrier. Probiotic bacteria have been shown to reinforce the different lines of gut defence: immune exclusion, immune elimination and immune regulation. On this basis, the strategy against allergic disease proposed here is based on the administration of tolerogenic gut-processed peptide fragments of a specific protein, in addition to the use of specific dietary compounds such as fatty acids and antioxidants, and introducing a microbial stimulus for the immature immune system by means of cultures of beneficial live micro-organisms characteristic of the healthy infant gut microbiota.
Isolauri
Erika
E
Department of Paediatrics, University of Turku, Turku, Finland. erika.isolauri@utu.fi
Ouwehand
Arthur C
AC
Laitinen
Kirsi
K
D015232:Dinoprostone / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007231:Infant, Newborn; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D007413:Intestinal Mucosa / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D018950:Lipopolysaccharide Receptors / Q000276:immunology; D016269:Milk Hypersensitivity / Q000276:immunology / Q000517:prevention & control*; D018384:Oxidative Stress / Q000502:physiology; D019936:Probiotics / Q000493:pharmacokinetics* / Q000627:therapeutic use*
D018950:Lipopolysaccharide Receptors; D007073:Immunoglobulin E; D015232:Dinoprostone